CN100381142C - A medicine for treating hepatitis - Google Patents
A medicine for treating hepatitis Download PDFInfo
- Publication number
- CN100381142C CN100381142C CNB2006100503735A CN200610050373A CN100381142C CN 100381142 C CN100381142 C CN 100381142C CN B2006100503735 A CNB2006100503735 A CN B2006100503735A CN 200610050373 A CN200610050373 A CN 200610050373A CN 100381142 C CN100381142 C CN 100381142C
- Authority
- CN
- China
- Prior art keywords
- parts
- liver
- medicine
- treatment
- radix
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Abstract
The present invention discloses a medicament for treating hepatic diseases, which is prepared from the following raw materials according to proportion by weight: 6 to 16 shares of honeysuckle flower, 3 to 12 shares of dandehon herb, 4 to 14 shares of Chinese angelica root and 1 to 11 shares of scrophularia root. The medicament is formed by processing traditional Chinese medicines in a refining mode according to the traditional Chinese medicine theory, and has effects of clearing away heat-toxin, stimulating blood circulation to end stasis; thus, the effect of treating both manifestation and root cause by diseases is achieved. The medicament of the present invention has unique treating effects on hepatic diseases and has few toxic side effects; in addition, the effective rate of the medicament is over 98%. Thereby, the present invention is particularly suitable for patients with fatty hepatic diseases and hepatic cirrhosis, and has definite treating effects on primary and medium-term hepatoma patients.
Description
[technical field]
The present invention relates to a kind of medicine for the treatment of hepatopathy, particularly be the hardened Chinese patent medicine of a kind of treatment fatty liver regulating liver-QI.
[background technology]
Raising along with people's living standard, while is along with the continuous deterioration of environment, especially the people who does not look after one's health and take exercise, the hepatopath is more and more in recent years, particularly fatty liver and liver cirrhosis patient, day by day the trend that increases is arranged, show according to interrelated data, fatty liver adult prevalence is 5～9%.The reason that causes fatty liver is a lot, as nutritional disorder, heavy drinking, diabetes, medicine damage and dyshormonia etc.A large amount of fat are piled up in hepatocyte, often make liver function damage, even cause fibrosis, finally liver cirrhosis take place, and cause adverse consequences.Patients with Fatty Liver is inappetence often, lassitude and weak, nausea and vomiting, hepatic region or upper right abdomen dull pain.Modern medicine is mainly etiological treatment to the treatment of fatty liver, cause that by releasing the different causes of disease that fatty liver takes place make it obtain taking a turn for the better or recovering, also use the medicine that promotes that liver is eliminated excess fat or stoped fat to store in liver, but curative effect depends on the type of fatty liver.The clinical medicine that is used for the treatment of fatty liver there is no sure curative effect at present, mainly is to replenish desired substance in the hepatocyte metabolic process, and the liver cirrhosis that the fatty liver later stage is occurred more lacks effective medicine.
The reason that causes liver cirrhosis is more, except above-mentioned fatty liver cause, be that hepatitis is to cause liver cirrhosis mostly.The symptom of early stage liver cirrhosis and fatty liver are identical substantially, also inappetence often, lassitude and weak, nausea and vomiting, hepatic region or upper right abdomen dull pain.B ultrasonic is common rough, and luminous point is fine and closely woven, and echo strengthens, and blood vessel network is unintelligible etc.At present, to the liver cirrhosis disease ideal medicine that also is of no curative effect, this mainly is because the pathological changes mechanism complexity of liver cirrhosis; the pathological changes phase shows not obvious clinically, and because its initial stage symptom complexity, feeling of patient is varied; thus be easy to take place mistaken diagnosis; up to the state of an illness with in entering, late period, clinical manifestation just can be diagnosed as liver cirrhosis when outstanding, thereby makes treatment and rehabilitation increase many difficulties.Modern medicine thinks that liver cirrhosis is because various paathogenic factors act on liver, disturbs and the destruction liver function, causes hepatic necrosis or alienation hypertrophy, develops into liver cirrhosis, causes liver function low and disorderly, until liver failure.Its Therapeutic Method is to protect the liver, to expand blood vessel, hemostasis diuresis, and by emergency measures such as surgical ligation blood vessels, so that relief of symptoms suitably prolongs patient's life, but these methods all do not reach the purpose of radical cure in case of necessity.
Chinese medicine thinks that the main etiology and pathogenesis of fatty liver is an eating and drinking without temperance, and surfeit greasy and surfeit flavour or heavy drinking make damp and hot interior giving birth to, or wet and gather into expectorant, causing damp-heat gluing each other, the retardance meridians make the stagnation of QI not all right, blood stasis resistance network, water-damp retention, thus a series of corresponding diseases take place.But the name of disease of fat-free liver on Chinese medicine, belongs to disease scopes such as " long-pending disease ", " fullness and oppression sensation in the epigastrium due to accumulation of phlegm " mostly according to its clinical performance.
Chinese medicine is called liver cirrhosis " tympanites ", thinks that " tympanites " sick formation is damp and hot, evil poison infringement liver and gall, brings disaster to taste, causes state of an illness delay, and the liver spleen restrains insult mutually, and dead blood glue coagulates due to the liver pulse.
Chinese medicine thinks that hepatocarcinoma is the focus that the liver rump, the liver abscess cause simultaneously, should adopt heat-clearing and toxic substances removing, and blood circulation promoting and blood stasis dispelling is separated stagnation of liver-QI and controlled it.
Though there is more inventor to disclose some Chinese prescriptions, these prescriptions curative effect clinically all also is not very desirable.
[summary of the invention]
Therefore, still there is demand in the Chinese medicine that people better treat hepatopathy to curative effect, the inventor is through prolonged and repeated research, and the checking repeatedly by clinical trial, finally find the treatment of better curative effect hepatopathy is arranged, particularly treat the hardened oral medicinal herb medicine of fatty liver regulating liver-QI, thereby finished the present invention.
Medicine of the present invention is to be guidance with the theory of Chinese medical science, according to the hardened traditional Chinese medical science pathology of fatty liver regulating liver-QI, and according to the principles of formulating prescriptions of heat-clearing and toxic substances removing, blood circulation promoting and blood stasis dispelling, the hardened new side of treatment fatty liver regulating liver-QI who develops.
The technical problem to be solved in the present invention provides a kind of treatment of treatment hepatopathy that more has, and particularly treats the hardened Chinese medicine composition of fatty liver regulating liver-QI.
Medicament selection Flos Lonicerae of the present invention, Herba Taraxaci, Radix Angelicae Sinensis, Radix Scrophulariae make up, and make each efficacy of drugs produce synergism these drug regimens, thereby can treat hepatopathy effectively.Wherein selecting Flos Lonicerae is monarch drug, for sweet in flavor and warm in property, nontoxic because of Flos Lonicerae.GUIXIN spleen lung Liver and kidney the five internal organs do not have through not going into, heat-clearing and toxic substances removing, and wind-heat dissipating is used for the warm blood fulminant dysentery, the carbuncle erysipelas.Selecting Herba Taraxaci for use is ministerial drug, is because the bitter gas of Herba Taraxaci nature and flavor is flat, nontoxic, goes into positive bright, lunar.It is hard swollen to burst, the tuberculosis that disappears, and Detoxicating food-poisoning, the gas that stagnates looses.Be used for jaundice due to damp-heat, the puckery pain of pyretic stranguria.Selecting for use when being classified as adjuvant drug, is because Radix Angelicae Sinensis nature and flavor Gan Xinwen can rise and can fall, and the YIN aspect of YANG is nontoxic, returns liver heart spleen channel, enrich blood and invigorate blood circulation, and menstruction regulating and pain relieving, loosening bowel to relieve constipation is used for blood deficiency and yellow complexion, asthenia cold abdominalgia, ulcer sores.Selecting Radix Scrophulariae for use is messenger drug, is because Radix Scrophulariae nature and flavor sweetness and bitterness is salty, is slightly cold, nontoxic, returns lung stomach kidney channel, the removing heat from blood YIN nourishing, and eliminating fire and detoxication is used for consumption of YIN caused by febrile disease, maculae caused by violent heat pathogen.In the crude drug of the present invention, particularly Flos Lonicerae gets Herba Taraxaci, and effect is bigger, and Herba Taraxaci is attacked more than benefit, and Flos Lonicerae is mended more than attacking, and the monarch and his subjects complement each other, and coordinating the actions of various ingredients in a prescription, play heat-clearing and toxic substances removing altogether, the merit of blood circulation promoting and blood stasis dispelling.
Medicine of the present invention also makes up with the Radix Paeoniae Alba, and this is because Radix Paeoniae Alba nature and flavor picric acid is flat, is slightly cold, and can rise and can fall, and the yang aspect of yin is returned the liver spleen channel, and strongly fragrant gas is from removing, and carbuncle is from disappearing, and heavily fortified point is long-pending from changing, and is used for costalgia, blood deficiency and yellow complexion.
In order to reach better therapeutic, medicine of the present invention also makes up with Calculus Bovis, Fel Serpentis.This is because of the sweet cold of Calculus Bovis nature and flavor, the GUIXIN Liver Channel, and the cool liver that clears away heart-fire, the endogenous wind stopping detoxifcation is used for the calentura coma, middle wind-phlegm fan; The liver spleen channel is returned in the cold of Fel Serpentis nature and flavor sweetness and bitterness, promoting the circulation of QI and reducing phlegm, and the liver benefiting that makes eye bright, heat-clearing and toxic substances removing, the damp eliminating of dispeling the wind is used for the liver-heat conjunctival congestion, gastric heat pain.
For to liver cirrhosis comparatively severe patient better therapeutic is arranged, medicine of the present invention makes up with Flos Carthami on above-mentioned basis again.This is because of the Flos Carthami property and flavor of peppery and warm, the GUIXIN Liver Channel, and promoting blood circulation to restore menstrual flow, eliminating stasis to stop pain, it is not all right to be used for lochia, the lump in the abdomen mass in the abdomen.
The consumption of each component of medicine of the present invention also sums up out through groping in a large number, and each component has better curative effect in the following weight parts scope:
6～16 parts of Flos Loniceraes, 3～12 parts of Herba Taraxacis, 4～14 parts of Radix Angelicae Sinensis, 1～11 part of Radix Scrophulariae.
Be preferably: 10 parts of Flos Loniceraes, 5 parts of Herba Taraxacis, 7 parts of Radix Angelicae Sinensis, 3 parts of Radix Scrophulariaes.
Each component of medicine of the present invention also can be 6～16 parts of Flos Loniceraes, 3～12 parts of Herba Taraxacis, 4～14 parts of Radix Angelicae Sinensis, 1～11 part of Radix Scrophulariae, 4～14 parts of the Radix Paeoniae Albas.
Be preferably: 10 parts of Flos Loniceraes, 5 parts of Herba Taraxacis, 7 parts of Radix Angelicae Sinensis, 3 parts of Radix Scrophulariaes, 7 parts of the Radix Paeoniae Albas.
Each amounts of components of medicine of the present invention can also be 6～16 parts of Flos Loniceraes, 3～12 parts of Herba Taraxacis, 4～14 parts of Radix Angelicae Sinensis, 1～11 part of Radix Scrophulariae, 4～14 parts of the Radix Paeoniae Albas, 0.05～0.5 part of Calculus Bovis, 0.05～0.5 part of Fel Serpentis.
Be preferably: 10 parts of Flos Loniceraes, 5 parts of Herba Taraxacis, 7 parts of Radix Angelicae Sinensis, 3 parts of Radix Scrophulariaes, 7 parts of the Radix Paeoniae Albas, 0.1 part of Calculus Bovis, 0.1 part of Fel Serpentis.
Each amounts of components of medicine of the present invention can also be 6～16 parts of Flos Loniceraes, 3～12 parts of Herba Taraxacis, 4～14 parts of Radix Angelicae Sinensis, 1～11 part of Radix Scrophulariae, 4～14 parts of the Radix Paeoniae Albas, 0.05～0.5 part of Calculus Bovis, 0.05～0.5 part of Fel Serpentis, 0.1～1 part on Flos Carthami.
Be preferably: 10 parts of Flos Loniceraes, 5 parts of Herba Taraxacis, 7 parts of Radix Angelicae Sinensis, 3 parts of Radix Scrophulariaes, 7 parts of the Radix Paeoniae Albas, 0.1 part of Calculus Bovis, 0.1 part of Fel Serpentis, 0.2 part on Flos Carthami.
Medicine of the present invention can adopt the conventional method of Chinese medicine preparation to be prepared into any conventional oral preparations.
Medicine of the present invention, has blood circulation promoting and blood stasis dispelling, heat-clearing and toxic substances removing, separate the effect of the liver rump, stagnation of liver-QI, the liver abscess, has original curative effect for fatty liver, liver cirrhosis especially, liver cancer patient first, mid-term is also had certain curative effect, and the hepatic cyst, cyst of kidney, metrocystosis and the ovarian cyst that cause for hepatopathy simultaneously also have good curative effect.
[specific embodiment]
Below further set forth the beneficial effect of medicine of the present invention by clinical trial example.
The prescription of medicine embodiment of the present invention is such: Flos Lonicerae 60～160g, Herba Taraxaci 30～120g, Radix Angelicae Sinensis 40～140g, the Radix Paeoniae Alba 40～140g, Radix Scrophulariae 10～110g, Calculus Bovis 0.5～5g, Fel Serpentis 0.5～5g.With being decocted in water for oral dose, good effect is also arranged, for with medicine mass production of the present invention, obtain better therapeutic, need to use modern equipment to produce in batches and become to take orally the type preparation, specifically be prepared from like this: take by weighing 50 kilograms of Flos Loniceraes, 25 kilograms of Herba Taraxacis and 35 kilograms of Radix Angelicae Sinensis are clean with cold water flush, take by weighing 15 kilograms of Radix Scrophulariaes again, 35 kilograms of the Radix Paeoniae Albas, 0.5 kilogram of Calculus Bovis, 0.5 kilogram of Fel Serpentis and Flos Lonicerae, Herba Taraxaci and Radix Angelicae Sinensis are put into the method extraction that Chinese medicine extraction jar water is proposed together, the temperature of Chinese medicine extraction jar is controlled at 50～85 ℃ under vacuum condition, make its boiling 2～4 hours, extract its circulation concentrated, proportion is 1～1.3 extractum, the extractum that makes is placed in the Alcohol-settling tank, the ethanol of adding 50～75%, stir precipitate with ethanol after 10～30 minutes, the supernatant of getting behind the precipitate with ethanol concentrates again, obtain proportion after concentrating once more and be 1～1.3 extractum, with this extractum oven dry, add adjuvant, the part by weight of extractum and adjuvant is 4: 1 or 5: 1, described adjuvant can be mannitol or starch, and extractum and adjuvant are stirred pulverizing together, promptly becomes the granular preparation of medicine of the present invention; Medicine after pulverizing is carried out tabletting, just become tablet; Medicine after pulverizing is put into capsule, just become capsule.When medicine of the present invention was made capsule, its every capsule was 0.47g.Below just the clinical trial that the patient did is observed by taking this capsule preparations.The clinical trial of medicine of the present invention is respectively to Patients with Fatty Liver, liver cirrhosis patient and liver cancer patient routine tests.At first be clinical trial to Patients with Fatty Liver:
1, physical data
Accept out-patient's 68 examples for medical treatment, wherein male 66 examples, women 2 examples, M-F is 33: 1.20～30 years old 2 age example, 30～40 years old 34 example, 40～50 years old 20 example, 12 examples more than 50 years old.Wherein professional cadre 55 people, teacher 10 people, workman 1 people, driver 1 people, peasant 1 people.
2, diagnostic criteria
Patients with Fatty Liver is inappetence all, lassitude and weak, and nausea and vomiting, xerostomia, bitter taste, hepatic region or upper right abdomen dull pain, blood examination is looked into triglyceride and is higher than 0.8mmol/L.Slight or the moderate increase of liver is found in ultrasound diagnosis, and the contrast of Liver and kidney echo obviously strengthens, and vascular lake is fuzzy.
3, Therapeutic Method
With oral four times of medicament capsule preparation of the present invention every day, each 6,15 days is to serve on two courses of treatment course of treatment.
4, efficacy assessment standard
Produce effects: the triglyceride index is normal, and B ultrasonic liver echo is weakened, and the liver size is normal, and vascular lake is clear.
Take a turn for the better: appetite is normal, and is energetic, and the refreshing heart is happy, and mouth is not done, and mouth is not bitter, and six indexs such as hepatalgia minimizing have wherein four above persons after treatment.
Invalid: as not reach improvement standard person.
5, therapeutic outcome (see Table 1 and table 2)
Table 1 is observation of curative effect after treating
Table 2 is after treating 30 days, and sign, triglyceride and B ultrasonic are observed
| Symptom | Inappetence | Lassitude and weak | Nausea and vomiting | Xerostomia | Bitter taste | Dull pain in liver | Triglyceride is higher | Liver increases | Liver echo strengthens | Vascular lake is fuzzy |
| (example) treatment back (example) before the treatment | 55 1 | 60 1 | 43 0 | 33 2 | 65 2 | 43 3 | 67 0 | 63 1 | 66 1 | 65 2 |
| Total effective rate (%) | 98.2 | 98.3 | 100 | 93.9 | 96.9 | 93 | 100 | 98.4 | 98.5 | 96.9 |
In a word, in 30 days treatment, with Drug therapy 68 routine Patients with Fatty Liver of the present invention, produce effects 60 examples as a result, 7 examples that take a turn for the better, invalid 1 example, obvious effective rate is 88.2%, inefficiency is 1.5%, always effectively is 98.5%.
Next is to the clinical trial of liver cirrhosis than severe patient, and this trial drug is that the medicine among the above-mentioned preparation technology adds 1 kilogram of Flos Carthami again and makes up together and make capsule and use among the present invention.
1, physical data
Accept out-patient's 86 examples for medical treatment, wherein male 71 examples, women 15 examples, M-F is 4.73: 1.30～40 years old 9 age example, 40～50 years old 49 example, 28 examples more than 50 years old.Wherein professional cadre 52 people, teacher 24 people, workman 3 people, driver 2 people, peasant 5 people.
2, diagnostic criteria
The standard of B ultrasonic diagnosis liver cirrhosis, 1. liver dwindles, and peplos thickens, and is uneven; 2. liver parenchyma echo increases thick, uneven; 3. portal vein diameter 〉=14.0mm; 4. splenomegaly; 5. splenic vein diameter 〉=8.0mm; 6. superior mesenteric vein diameter 〉=12.0mm.More than possessing 3 is diagnosable liver cirrhosis.
3, Therapeutic Method
With oral four times of medicament capsule preparation of the present invention every day, each 6,30 days is a course of treatment, serve on three courses of treatment.
4, efficacy assessment standard
Produce effects: the liver size is normal, smooth surface; Liver parenchyma echo is even; Splenomegaly is little normal; Vascular lake is clear; Portal vein diameter＜14.0mm; Splenic vein diameter＜8.0mm; Superior mesenteric vein diameter＜12.0mm.Have wherein three and promptly be considered as produce effects.
Take a turn for the better: happy, appetite is normal, energetic, complexion is normal.
Invalid: as not reach improvement standard person.
5, therapeutic outcome (see Table 3 and table 4)
Table 3 is observation of curative effect after treating
Table 4 is after treating 45 days, and B ultrasonic is observed
| Symptom | Liver dwindles, and peplos thickens, and is uneven | Liver parenchyma echo increases slightly, inequality | Portal vein diameter 〉=14.0mm | Splenomegaly | Splenic vein diameter 〉=8.0mm | Superior mesenteric vein diameter 〉=12.0mm |
| (example) treatment back (example) before the treatment | 81 3 | 51 2 | 56 1 | 73 3 | 53 1 | 44 4 |
| Total effective rate (%) | 96.3 | 96.1 | 98.2 | 95.9 | 98.1 | 91 |
In a word, in 90 days treatment, with Drug therapy 86 routine liver cirrhosis patients of the present invention, produce effects 76 examples as a result, 9 examples that take a turn for the better, invalid 1 example, obvious effective rate is 88.4%, inefficiency is 1.1%, always effectively is 98.9%.
Be once more to just, mid-term liver cancer patient clinical trial, this trial drug also is that the medicine among the above-mentioned preparation technology adds 1 kilogram of Flos Carthami again and makes up together and make capsule and use among the present invention.
1, physical data
Accept out-patient's 13 examples for medical treatment, wherein male 9 examples, women 4 examples, M-F is 2.25: 1.30～40 years old 1 age example, 40～50 years old 5 example, 7 examples more than 50 years old.Wherein professional cadre 7 people, teacher 2 people, workman 1 people, driver 1 people, peasant 2 people.
2, diagnostic criteria
CT shows as unenhanced low-density or the nonhomogeneous density of being, and slight reinforcement or Heterogeneous enhancement are arranged after the enhancing, delaying sweep focus do not disappear (becoming isodensity with liver).
3, Therapeutic Method
With oral four times of medicament capsule preparation of the present invention every day, each 6,30 days is a course of treatment, serve on four courses of treatment.
4, efficacy assessment standard
Produce effects: CT shows as the unenhanced uniform density that is, and does not strengthen the delaying sweep foci disappearance after the enhancing.
Take a turn for the better: energetic, of pink and healthy-looking, hepatic region does not have pain.
Invalid: as not reach improvement standard person.
5, therapeutic outcome (see Table 5 and table 6)
Table 5 is observation of curative effect after treating
Table 6 after treating 120 days, the CT observation of developing
| Symptom | Low-density or nonhomogeneous density | Slight reinforcement or Heterogeneous enhancement are arranged after the enhancing | The delaying sweep focus does not disappear |
| (example) treatment back (example) before the treatment | 13 6 | 13 7 | 13 6 |
| Total effective rate (%) | 53.9 | 46.2 | 53.9 |
In a word, in 120 days treatment, with Drug therapy 13 routine liver cancer patients of the present invention, produce effects 5 examples as a result, 2 examples that take a turn for the better, invalid 6 examples, obvious effective rate is 38.59%, inefficiency is 46.1%, always effectively is 53.9%.
In sum, medicine of the present invention is all effective in cure to fatty liver and liver cirrhosis, and the curative effect rate reaches more than 98%, and toxic and side effects is little, and to just, the liver cancer patient in mid-term also has certain curative effect.Medicine of the present invention not only has good efficacy to fatty liver and liver cirrhosis patient through overtesting, and hepatic cyst, cyst of kidney, metrocystosis and the ovarian cyst that hepatopathy causes is also had good curative effect.
Claims (8)
1. medicine for the treatment of hepatopathy is characterized in that it is mainly made by following bulk drugs: 6～16 parts of Flos Loniceraes, 3～12 parts of Herba Taraxacis, 4～14 parts of Radix Angelicae Sinensis, 1～11 part of Radix Scrophulariae.
2. a kind of medicine for the treatment of hepatopathy according to claim 1 is characterized in that wherein the consumption of each crude drug is: 10 parts of Flos Loniceraes, 5 parts of Herba Taraxacis, 7 parts of Radix Angelicae Sinensis, 3 parts of Radix Scrophulariaes.
3. a kind of medicine for the treatment of hepatopathy according to claim 1 is characterized in that crude drug also has: 4～14 parts of the Radix Paeoniae Albas.
4. a kind of medicine for the treatment of hepatopathy according to claim 3 is characterized in that the consumption of each crude drug is: 10 parts of Flos Loniceraes, 5 parts of Herba Taraxacis, 7 parts of Radix Angelicae Sinensis, 3 parts of Radix Scrophulariaes, 7 parts of the Radix Paeoniae Albas.
5. a kind of medicine for the treatment of hepatopathy according to claim 3 is characterized in that crude drug also has: 0.05～0.5 part of Calculus Bovis, 0.05～0.5 part of Fel Serpentis.
6. a kind of medicine for the treatment of hepatopathy according to claim 5 is characterized in that the consumption of each crude drug is: 10 parts of Flos Loniceraes, 5 parts of Herba Taraxacis, 7 parts of Radix Angelicae Sinensis, 3 parts of Radix Scrophulariaes, 7 parts of the Radix Paeoniae Albas, 0.1 part of Calculus Bovis, 0.1 part of Fel Serpentis.
7. a kind of medicine for the treatment of hepatopathy according to claim 5 is characterized in that crude drug also has: 0.1～1 part on Flos Carthami.
8. a kind of medicine for the treatment of hepatopathy according to claim 8 is characterized in that each crude drug consumption is: 10 parts of Flos Loniceraes, 5 parts of Herba Taraxacis, 7 parts of Radix Angelicae Sinensis, 3 parts of Radix Scrophulariaes, 7 parts of the Radix Paeoniae Albas, 0.1 part of Calculus Bovis, 0.1 part of Fel Serpentis, 0.2 part on Flos Carthami.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2006100503735A CN100381142C (en) | 2006-04-13 | 2006-04-13 | A medicine for treating hepatitis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2006100503735A CN100381142C (en) | 2006-04-13 | 2006-04-13 | A medicine for treating hepatitis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1876061A CN1876061A (en) | 2006-12-13 |
| CN100381142C true CN100381142C (en) | 2008-04-16 |
Family
ID=37508730
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2006100503735A Expired - Fee Related CN100381142C (en) | 2006-04-13 | 2006-04-13 | A medicine for treating hepatitis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100381142C (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105125766A (en) * | 2015-09-09 | 2015-12-09 | 白玛仁增 | Compound Tibetan medicine preparation for treating fatty liver and alcoholic liver, expelling gall bladder and intestine roundworms and detoxifying |
| CN105853504B (en) * | 2016-04-01 | 2020-01-21 | 叶善中 | Anti-tumor beverage |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1257719A (en) * | 1998-12-22 | 2000-06-28 | 王治隆 | Medicinal pill for eliminating fat and beautifying face |
| CN1120715C (en) * | 2000-10-18 | 2003-09-10 | 沈丕安 | Fatty liver treating Chinese medicine |
| CN1686210A (en) * | 2005-04-08 | 2005-10-26 | 齐柏山 | Traditional Chinese medicinal preparation for treating hepatitis B |
-
2006
- 2006-04-13 CN CNB2006100503735A patent/CN100381142C/en not_active Expired - Fee Related
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1257719A (en) * | 1998-12-22 | 2000-06-28 | 王治隆 | Medicinal pill for eliminating fat and beautifying face |
| CN1120715C (en) * | 2000-10-18 | 2003-09-10 | 沈丕安 | Fatty liver treating Chinese medicine |
| CN1686210A (en) * | 2005-04-08 | 2005-10-26 | 齐柏山 | Traditional Chinese medicinal preparation for treating hepatitis B |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1876061A (en) | 2006-12-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101884770B (en) | Chinese medicinal preparation for treating urolithiasis and preparation method thereof | |
| CN102526616B (en) | Chinese medicinal herb pills for treating cholecystitis and gallstone | |
| CN102205107B (en) | Chinese medicinal preparation for treating duodenal ulcer and preparation method thereof | |
| CN104055965A (en) | Oral administration medicine for treating haemorrhoids and application thereof | |
| CN102441081A (en) | Medicament for treating gout and its preparation method | |
| CN105169214A (en) | Traditional Chinese medicine composition for treating atherosclerosis, and preparation method thereof | |
| CN106266463A (en) | A kind of Chinese medicine composition for treating hyperuricemia and application thereof | |
| CN102847074B (en) | Blood stasis removing pill for treating ankylosing spondylitis | |
| CN104524481B (en) | A kind of Chinese medicine for treating IBS and preparation method thereof | |
| CN100381142C (en) | A medicine for treating hepatitis | |
| CN106039109A (en) | Traditional Chinese medicinal liquor for preventing and treating cold dampness accumulation pattern rheumatoid arthritis | |
| CN102145143B (en) | Pharmaceutical composition for treatment of gastritis and preparation method of pharmaceutical composition | |
| CN103893611A (en) | Drug for treating kidney stone and preparation method of drug | |
| CN102580032B (en) | Chinese medicinal composition tablets, powder and oral liquid with effect of promoting urinary calculus removal and preparation method thereof | |
| CN104800675A (en) | Medicament for treating active ulcerative colitis | |
| CN104689239A (en) | Traditional Chinese medicine composition for treating cholelithiasis and preparation method thereof | |
| CN104474445A (en) | Traditional Chinese medicine preparation for treating pernicious vomiting disease | |
| CN104189615B (en) | Traditional Chinese medicine preparation for treating metrorrhagia and metrostaxis, and preparation method of traditional Chinese medicine preparation | |
| CN106177773A (en) | A kind of Chinese medicinal pill treating urinary system calculus | |
| CN106822852A (en) | Treat pharmaceutical composition, its preparation technology and the purposes of coronary heart disease | |
| CN104367862A (en) | Traditional Chinese medicinal composition for treating urethral calculus | |
| CN104645225A (en) | Traditional Chinese medicine preparation for treating chronic hepatobiliary diseases | |
| CN117942383A (en) | Traditional Chinese medicine composition and preparation for treating acute thrombotic external hemorrhoids and preparation method thereof | |
| CN103861077B (en) | A kind of preparation of effective treatment acute pancreatitis | |
| CN103446361B (en) | A kind of Chinese medicine composition for the treatment of stagnation of phlegm-damp in middle-JIAO type fatty liver |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20080416 Termination date: 20120413 |